Drug intelligence / Profile preview

LTM1201LN

Development stage: Phase 2
Lead developer: Brigham and Women's Hospital
Modality: Small Molecules
Administration: Oral

Overview

**LTM1201LN** is an investigational oral combination of **lorcaserin** and **nabilone** evaluated by Brigham and Women's Hospital for obstructive sleep apnea. Lorcaserin is a selective serotonin 2C receptor agonist intended to increase hypoglossal motor output and upper-airway dilator-muscle activity during sleep, while nabilone is a synthetic cannabinoid receptor agonist. The combination was studied as a pre-sleep pharmacologic approach to reduce upper-airway collapsibility and obstructive sleep apnea severity.

Other names: lorcaserin + nabilone

Targets

NET (Norepinephrine Transporter)mAChR (Muscarinic acetylcholine receptors)

Beyond the preview

Go deeper on LTM1201LN.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LTM1201LN.

Explore the full profile